News Archive

ROCKVILLE, MARYLAND, September 26, 2022 – When it was announced that the winner of the 7^th Annual BioHealth Capital Region Crab Trap would be the recipients of a larger than ever prize pool, organizers didn’t expect that two companies would benefit thanks to unique circumstances. The main winner, Neuroene Therapeutics, a biotech company focused on discovering, developing, and commercializing novel therapeutics for difficult-to-treat neurological disorders, was selected from five finalists as the company with the most commercial potential at the 7^th Annual Crab Trap Competition.

Gaithersburg-based Neuroene Therapeutics and its approach to treating a rare form of epilepsy were crowned the winner of the seventh annual Crab Trap Competition, which highlights the commercialization potential of biohealth technologies throughout the BioHealth Capital Region.

The company was largely recognized for its lead asset, NT102, a Vitamin K analog demonstrating broad seizure protection in preclinical animal models. In particular, the asset showed protection against seizures in Dravet syndrome, a rare genetic disease marked by severe encephalopathy and epilepsy that doesn’t respond well to current medications.

BaneBio is proud to be a sponsor of this invite-only VIP panel event I-270 Innovation Labs.

Startups. Capital. Entrepreneurship. These weren’t always terms in Amy White’s daily lexicon.

A trained scientist, White dedicated 15 years to teaching microbiology, focusing on the world that happens within the laboratory.

“I really never thought beyond the pipette, right,” she recalled at a recent biotech event, Game Changer Week, that was organized in Roanoke.

Emergent BioSolutions, already flush with products against public health threats like anthrax attacks and opioid overdoses, is expanding its arsenal of medical countermeasures by scooping up global rights to smallpox newcomer Tembexa.

Emergent will furnish developer Chimerix with $225 million in upfront cash plus upward of $100 million in milestone payments for worldwide rights to the med, also known as brincidofovir. The drug last summer snagged FDA approval as the first antiviral cleared to treat smallpox regardless of a patient’s age.

The Small Business Innovation Research program is a big step further away from ending.

The Senate passed a three-year authorization of SBIR and the Small Business Technology Transfer Research program by unanimous consent on Sept. 20.

Sen. Ben Cardin (D-Md.), chairman of Committee on Small Business and Entrepreneurship, introduced and the full body passed the SBIR and STTR Extension Act of 2022 on Wednesday after several months of delay because of concerns from Sen. Rand Paul (R-Ky.) about companies abusing the program.

Image: Sen. Ben Cardin (D-Md.) is the chairman of the Committee on Small Business and Entrepreneurship. – https://federalnewsnetwork.com

Fifth Milestone Achieved by HemoShear with Novel Compounds for Second Target

CHARLOTTESVILLE, Va., Sept. 21, 2022 /PRNewswire/ — HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has earned a milestone payment for the advancement of potential lead product candidates against a second target for the treatment of gout under its collaboration with Horizon Therapeutics plc ( Nasdaq: HZNP). This milestone marks the fifth payment that HemoShear has earned in accordance with the Horizon exclusive drug discovery agreement established in January 2019.

Doubling the University of Maryland BioPark’s lab space, the two-phase 4MLK development project will represent more than $320 million in total capital investment

BALTIMORE, Sept. 22, 2022 /PRNewswire/ — University of Maryland, Baltimore (UMB) and Wexford Science & Technology, LLC, announced today that 4MLK, the newest development project in the University of Maryland BioPark, is slated to move forward, with groundbreaking this fall (2022) and delivering in summer 2024. The 8-story, 250,000-square-foot building, Phase I of a two-phase project representing a $320 million total capital investment, will provide critical wet laboratory space in downtown Baltimore for researchers and companies, flexible lab and office/support space for start-ups, and Class A office space, along with areas for convening and a conference center.

ROCKVILLE, Md., Sept. 21, 2022 (GLOBE NEWSWIRE) — MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research, as well as next-generation cell therapeutic discovery, development and commercialization, today announced that it has relocated its headquarters to 9713 Key West Avenue in Rockville, Maryland, 20850, within Maryland’s I-270 Biotech Corridor. The Company’s new 67,000 square-foot facility significantly increases its in-house manufacturing capacity, as well as research and process development lab space. This investment represents a major milestone in MaxCyte’s growth and its ability to support customers and partners in their journey through therapeutic development to commercialization.